Belite Bio To Present Topline Data From Phase 3 DRAGON Study Of Stargardt Disease Type 1 Treatment At 27th Fundus Disease Forum And International Retinal Symposium
Belite Bio Inc BLTE
$143.00
▼ -4.63%
($-6.95)
Open
$149.77
Prev Close
$149.95
Day Range
$141.34 – $149.95
52W Range
$56.10 – $200.00
Market Cap
$5.99B
Beta
-1.20
EPS (TTM)
$-2.42
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-04-29 |
| Shares Out. | 39,970,000 |
| Website | belitebio.com/ ↗ |
| Phone | 18582466240 |
Belite Bio Inc is a publicly traded company under the ticker symbol BLTE on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-05-01)
📰 Latest News for BLTE
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
Belite Bio, Inc (BLTE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Transcript : Belite Bio, Inc Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 03
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
Belite Bio, Inc (BLTE) Presents at FFB Retinal Therapeutics Innovation Summit - Slideshow